Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Altimmune, Inc. stock logo
ALT
Altimmune
$4.82
+1.4%
$6.16
$4.63
$11.16
$370.13M0.872.92 million shs316,651 shs
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
$158.07
+0.1%
$178.23
$123.00
$257.40
$4.68B1.48586,397 shs67,397 shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$800.67
-0.6%
$847.53
$711.40
$972.53
$759.27B0.343.30 million shs163,116 shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$67.68
-0.5%
$81.89
$66.81
$148.15
$303.71B0.425.56 million shs525,912 shs
ResMed Inc. stock logo
RMD
ResMed
$220.27
-0.9%
$232.86
$172.19
$263.05
$32.35B0.74996,579 shs26,853 shs
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
$24.43
+2.2%
$29.94
$23.27
$81.86
$2.74B0.93.89 million shs327,437 shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Altimmune, Inc. stock logo
ALT
Altimmune
-5.20%-19.52%-28.72%-34.26%-53.67%
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
-1.17%-4.62%-14.99%-14.91%-24.73%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
-2.63%-5.71%-12.68%+4.11%+5.76%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
-2.27%-7.57%-25.00%-20.95%-46.69%
ResMed Inc. stock logo
RMD
ResMed
-0.75%+0.33%-4.79%-2.87%+17.37%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-0.99%-14.55%-17.18%-40.58%-69.92%
Remove Ads
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Altimmune, Inc. stock logo
ALT
Altimmune
2.5078 of 5 stars
3.41.00.00.02.73.30.6
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
4.8963 of 5 stars
4.43.00.04.83.82.51.9
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
4.9471 of 5 stars
3.45.03.34.03.42.51.9
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
4.8252 of 5 stars
4.45.02.50.02.00.04.4
ResMed Inc. stock logo
RMD
ResMed
4.5157 of 5 stars
3.31.03.34.53.01.71.3
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
4.2191 of 5 stars
4.51.00.04.72.12.50.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Altimmune, Inc. stock logo
ALT
Altimmune
2.89
Moderate Buy$20.83332.68% Upside
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
2.70
Moderate Buy$226.7043.42% Upside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.85
Moderate Buy$1,009.7226.11% Upside
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
2.80
Moderate Buy$145.25114.62% Upside
ResMed Inc. stock logo
RMD
ResMed
2.67
Moderate Buy$249.7313.38% Upside
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
3.00
Buy$95.18289.69% Upside

Current Analyst Ratings Breakdown

Latest LLY, NVO, VKTX, ALT, RMD, and INSP Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/26/2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$102.00 ➝ $102.00
3/19/2025
ResMed Inc. stock logo
RMD
ResMed
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$280.00
3/18/2025
Altimmune, Inc. stock logo
ALT
Altimmune
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$12.00 ➝ $12.00
3/14/2025
Altimmune, Inc. stock logo
ALT
Altimmune
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform
3/13/2025
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
Kepler Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy
3/11/2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$102.00 ➝ $102.00
3/6/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$1,146.00
3/5/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$970.00 ➝ $1,100.00
3/5/2025
ResMed Inc. stock logo
RMD
ResMed
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy
3/5/2025
ResMed Inc. stock logo
RMD
ResMed
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold ➝ Hold$250.00 ➝ $240.00
3/3/2025
Altimmune, Inc. stock logo
ALT
Altimmune
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$12.00 ➝ $12.00
(Data available from 4/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Altimmune, Inc. stock logo
ALT
Altimmune
$20K18,541.12N/AN/A$2.75 per share1.75
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
$802.80M5.86$1.51 per share104.41$23.25 per share6.80
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$45.04B16.85$13.05 per share61.34$15.05 per share53.20
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$290.40B1.05$3.14 per share21.57$4.64 per share14.59
ResMed Inc. stock logo
RMD
ResMed
$4.93B6.57$8.73 per share25.23$35.77 per share6.16
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/AN/AN/AN/A$3.48 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Altimmune, Inc. stock logo
ALT
Altimmune
-$88.45M-$1.34N/AN/AN/A-199,076.92%-55.81%-50.60%5/8/2025 (Estimated)
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
$53.51M$1.7390.9749.092.866.67%8.19%7.09%5/6/2025 (Estimated)
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$10.59B$11.7168.3825.731.4023.51%85.24%16.19%5/1/2025 (Estimated)
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$14.64B$3.2920.5714.520.9034.81%84.68%26.29%5/1/2025 (Estimated)
ResMed Inc. stock logo
RMD
ResMed
$1.02B$8.4726.0121.261.5325.34%26.17%18.60%4/24/2025 (Estimated)
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$109.96M-$1.00N/AN/AN/AN/A-11.93%-11.57%4/23/2025 (Estimated)

Latest LLY, NVO, VKTX, ALT, RMD, and INSP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/24/2025N/A
ResMed Inc. stock logo
RMD
ResMed
$2.37N/AN/AN/A$1.28 billionN/A
4/23/2025N/A
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$0.34N/AN/AN/AN/AN/A
2/27/2025Q4 2024
Altimmune, Inc. stock logo
ALT
Altimmune
-$0.34-$0.33+$0.01-$0.33$0.00 million$0.01 million
2/10/2025Q4 2024
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
$0.74$1.15+$0.41$1.15$239.76 millionN/A
2/6/2025Q4 2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.45$5.32-$0.13$4.88$13.42 billionN/A
2/5/2025Q4 2024
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.88$0.91+$0.03$0.91N/AN/A
2/5/2025Q4 2024
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$0.27-$0.32-$0.05-$0.32N/AN/A
1/30/2025Q2 2025
ResMed Inc. stock logo
RMD
ResMed
$2.29$2.43+$0.14$2.34$1.27 billionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Altimmune, Inc. stock logo
ALT
Altimmune
N/AN/AN/AN/AN/A
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
N/AN/AN/AN/AN/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.000.75%+15.21%51.24%11 Years
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$1.572.32%+25.26%47.72%N/A
ResMed Inc. stock logo
RMD
ResMed
$2.120.96%+7.63%25.03%13 Years
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/AN/AN/AN/AN/A

Latest LLY, NVO, VKTX, ALT, RMD, and INSP Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/5/2025
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
semi-annual$0.78741.2%3/31/20253/31/20254/8/2025
1/30/2025
ResMed Inc. stock logo
RMD
ResMed
quarterly$0.530.9%2/13/20252/13/20253/20/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Altimmune, Inc. stock logo
ALT
Altimmune
N/A
16.87
16.87
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
N/A
7.13
6.22
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.00
1.15
0.97
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.62
0.74
0.55
ResMed Inc. stock logo
RMD
ResMed
0.13
3.33
2.29
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/A
36.47
36.47

Institutional Ownership

CompanyInstitutional Ownership
Altimmune, Inc. stock logo
ALT
Altimmune
78.05%
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
94.91%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
11.54%
ResMed Inc. stock logo
RMD
ResMed
54.98%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
76.03%
CompanyEmployeesShares OutstandingFree FloatOptionable
Altimmune, Inc. stock logo
ALT
Altimmune
5077.01 million68.21 millionOptionable
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
1,24629.76 million28.45 millionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
39,000948.17 million948.08 millionOptionable
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
54,4004.49 billion4.48 billionOptionable
ResMed Inc. stock logo
RMD
ResMed
8,160146.87 million145.82 millionOptionable
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
20112.25 million106.20 millionOptionable

Recent News About These Companies

Viking Therapeutics Sees Unusually High Options Volume (NASDAQ:VKTX)
Modern medical technology system and devices - stock image
Which Healthcare Stock Is the Best Buy Right Now?
Viking Therapeutics completes enrollment in Phase 2 trial of VK2735

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Altimmune stock logo

Altimmune NASDAQ:ALT

$4.82 +0.07 (+1.37%)
As of 10:11 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Inspire Medical Systems stock logo

Inspire Medical Systems NYSE:INSP

$158.06 +0.09 (+0.05%)
As of 10:10 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. It also develops a novel, closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The company was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.

Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$800.67 -4.56 (-0.57%)
As of 10:11 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Novo Nordisk A/S stock logo

Novo Nordisk A/S NYSE:NVO

$67.68 -0.35 (-0.52%)
As of 10:11 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

ResMed stock logo

ResMed NYSE:RMD

$220.26 -2.04 (-0.92%)
As of 10:11 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

Viking Therapeutics stock logo

Viking Therapeutics NASDAQ:VKTX

$24.42 +0.52 (+2.15%)
As of 10:11 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.